News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

SALVAT Announces The FDA Acceptance Of NDA For Its CETRAXAL Otic Solution


10/19/2005 5:09:20 PM

BARCELONA, Spain--(BUSINESS WIRE)--Sept. 14, 2005--SALVAT announced that the New Drug Application (NDA) for its CETRAXAL Otic -ciprofloxacin otic- 0.2% Solution, for the Treatment of External Otitis has been accepted for review by the U.S. Food and Drug Administration (FDA).

Read at BioSpace.com

comments powered by Disqus
   
Otitis

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES